Close Menu

NEW YORK (GenomeWeb) – Precision oncology diagnostic firm MolecularMD has received authorization from the US Food and Drug Administration for a test to help physicians determine whether a patient with chronic myeloid leukemia (CML) can stop treatment with Novartis' drug Tasigna (nilotinib). 

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

May
13
Sponsored by
LGC SeraCare Life Sciences

As we pass the one-year anniversary of both the COVID-19 pandemic and the first Emergency Use Authorized SARS-CoV-2 PCR detection assays, there remains significant opportunity for clinical laboratories to advance testing and support improved patient management.